HCW Biologics Inc.
For the period ended Jun 30, 2025. Filed Aug 18, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 18, 2025
HCWB$1.02-1.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of changes in stockholders’ equity (deficit)
Condensed Statements of Changes in Stockholders’ Equity (Deficit)
For the Six Months Ended June 30, 2024 and 2025
| Stockholders’ Equity (Deficit) | |||||
|---|---|---|---|---|---|
| Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders’ | |||||
| Shares | Amount | Capital | Deficit | Equity (Deficit) | |
| Balance, January 1, 2024 | 900,628 | $90 | $83,993,950 | $(70,532,323) | $13,461,717 |
| Issuance of Common Stock upon exercise of stock options | 314 | 1 | 2,254 | — | 2,255 |
| Issuance of Common Stock upon equity subscription | 44,643 | 4 | 2,500,001 | — | 2,500,005 |
| Stock-based compensation | — | — | 244,685 | — | 244,685 |
| Net loss | — | — | — | (7,468,061) | (7,468,061) |
| Balance, March 31, 2024 | 945,585 | $95 | $86,740,890 | $(78,000,384) | $8,740,601 |
| Issuance of Common Stock upon exercise of stock options | — | — | — | — | — |
| Stock-based compensation | — | — | 239,821 | — | 239,821 |
| Net loss | — | — | — | (15,280,191) | (15,280,191) |
| Balance, June 30, 2024 | 945,585 | $95 | $86,980,711 | $(93,280,575) | $(6,299,769) |
| Stockholders’ Deficit | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders’ | |||||||||
| Shares · Amount · Capital · Deficit · Deficit | |||||||||
| Balance, January 1, 2025 | 1,113,532 | $111 | $93,785,854 | $(100,556,137) | $(6,770,172) | ||||
| Issuance of Common Stock upon exercise of stock options | 205 | — | 1,654 | — | 1,654 | ||||
| Issuance of Common Stock to Square Gate | 9,616 | 1 | 149,999 | — | 150,000 | ||||
| Issuance cost of Common Stock | — | — | (22,297) | — | (22,297) | ||||
| Stock-based compensation | — | — | 275,642 | — | 275,642 | ||||
| Net loss | — | — | — | (2,196,875) | (2,196,875) | ||||
| Balance, March 31, 2025 | 1,123,353 | $112 | $94,190,852 | $(102,753,012) | $(8,562,048) | ||||
| Issuance of Common Stock | 194,242 | 20 | 1,592,784 | — | 1,592,804 | ||||
| Issuance of pre-funded warrants | — | — | 4,207,718 | — | 4,207,718 | ||||
| Issuance of common stock warrants | — | — | 9,650,404 | — | 9,650,404 | ||||
| Exercise of pre-funded warrants | 513,140 | 51 | - | — | 51 | ||||
| Issuance cost of Common Stock | — | — | (70,094) | — | (70,094) | ||||
| Issuance cost of pre-funded warrants | — | — | (504,862) | — | (504,862) | ||||
| Issuance cost of common stock warrants | — | — | (227,646) | — | (227,646) | ||||
| Equity dividend to investor | (10,153,799) | (10,153,799) | |||||||
| Issuance of Common Stock to extinguish restructured debt | 253,083 | 25 | 1,774,087 | — | 1,774,112 | ||||
| Issuance of common stock warrants to extinguish restructured debt | 544,249 | — | 544,249 | ||||||
| Gain on conversion of debt with related parties, net | — | — | 3,346,562 | — | 3,346,562 | ||||
| Stock-based compensation | — | — | 278,307 | — | 278,307 | ||||
| Adjustment for reverse stock split | 62,783 | 7 | (7) | — | - | ||||
| Net loss | — | — | - | (1,927,730) | (1,927,730) | ||||
| Balance, June 30, 2025 | 2,146,601 | $215 | $104,628,555 | $(104,680,742) | $(51,972) | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.